查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439214

全球老年黃斑部病變(AMD)市場評估:按疾病,藥物類型,給藥途徑,最終用戶,分銷管道,地區,機會和預測（2017-2031）

Age Related Macular Degeneration Market Assessment, By Disease, By Drug Type, By Route of Administration, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球老年黃斑部病變（AMD）市場規模將從2023年的101.9億美元增至2031年的212.2億美元，預計2024-2031年預測期間內複合年增長率為9.6%。近年來，該市場呈現顯著成長，預計在預測期內將進一步擴大。

根據Journal Cureus發表的一篇文章，預計到 2022 年 9 月，將有 2 億人患有 AMD。到 2040 年，這一數字預計將增加至約 3 億。年齡相關性黃斑部病變 (AMD) 市場的成長歸功於世界各地各個衛生組織和非政府組織不斷努力，以提高人們對適當治療過程和這種疾病影響的認識。Masu。

市場公司加大投資支持市場擴張

老年黃斑部病變（AMD）在世界各地的盛行率不斷上升，促使多個市場參與者和研究機構開發治療方案和早期診斷解決方案來對抗這種疾病。我們正在投資。例如，Adverum Biotechnologies, Inc. 正在開發 Ixoberogene soroparvovec (Ixo-vec) 作為濕性 AMD 的治療方法。此臨床階段基因治療候選產品採用專有載體 AAV.7m8。AAV.7m8 在其自身表達盒的控制下攜帶阿柏西普的編碼序列。目前濕性AMD的治療需要頻繁地眼內注射抗VEGF藥物，這對護理人員和患者都造成了負擔。Adverum 有潛力提供一種經濟高效、持久且安全的眼內治療選擇，滿足全球視網膜專家、醫療保健系統以及患者及其照護者的需求。一項患者研究表明，Ixoberogene soroparvovec 對濕性 AMD 受試者俱有一致且持續的治療水平。

人口老化加劇推動市場發展

由於老年人口不斷增加，預計預測期內對 AMD 治療藥物的需求將會增加。由於老年人口黃斑部病變的風險較高，預計市場將隨著老年人口的增加而擴大。據世界衛生組織 (WHO) 稱，到 2030 年，全球六分之一的人口將超過 60 歲。到2050年，全球60歲以上人口將達21億，80歲以上人口將達4.26億。

美國疾病管制與預防中心 (CDC) 估計，美國有 730 萬人因老年黃斑部病變 (AMD) 而面臨視力喪失的高風險，其中 180 萬人患有這種疾病。這些因素正在推動黃斑部病變治療市場的成長。

北美佔有很大的市場份額

老年人口的增加、多個市場參與者的存在以及年齡相關性黃斑部病變 (AMD) 患者數量的增加正在支持該地區的市場擴張。據估計，美國約有 2000 萬成年人患有某種形式的黃斑部病變。據Canadian Ophthalmological Society稱，年齡相關性黃斑部病變 (AMD) 是加拿大失明的主要原因之一，截至 2022 年 2 月，約有 200 萬加拿大人受到影響。

會議將透過重點介紹加拿大眼科醫生進行的研究來提高人們對不同治療方法的認識，這些研究致力於創新旨在增強濕性 AMD 治療的新療法。我們致力於傳播這一訊息。老年黃斑部病變 (AMD) 研究已在多個領域顯示出前景。各種新療法的化學試驗正在進行中，旨在增加 AMD 的治療選擇。這些針對老年性黃斑部病變（AMD）治療方法的持續投資和努力進一步推動了北美老年黃斑部病變（AMD）市場的擴張。

本報告研究和分析了全球年齡相關性黃斑部病變（AMD）市場，提供市場規模和預測、市場動態以及主要參與者的現狀和前景。

目錄

第一章研究方法論

第二章 專案範圍與定義

第3章執行摘要

第四章全球老年黃斑部病變（AMD）市場展望（2017-2031）

  • 市場規模及預測
    • 金額
    • 數量
  • 疾病
    • 濕AMD
    • 乾性AMD
    • 其他
  • 藥物類型
    • 阿柏西普（Eylea）
    • 雷珠單抗（Lucentis）
    • 貝伐珠單抗（阿瓦斯汀）
    • □加他尼（Macgen）
    • 維替泊芬（維替泊芬）
    • Brolucizumab（Beovu）
    • 補充
    • 其他
  • 給藥途徑
    • 靜脈
    • 玻璃體
  • 最終用戶
    • 免疫科醫院
    • 專科診所
    • 門診手術中心
    • 家庭醫療
    • 其他
  • 分銷渠道
    • 醫院藥房
    • 零售藥店
    • 網上藥店
  • 區域
    • 北美
    • 南美洲
    • 歐洲
    • 亞太地區
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第5章全球老年黃斑部病變（AMD）市場展望：按地區（2017-2031）

  • 北美
    • 市場規模及預測
    • 疾病
    • 藥物類型
    • 給藥途徑
    • 最終用戶
    • 分銷渠道
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 南美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第六章 市場測繪（2023）

  • 按疾病分類
  • 依藥物類型
  • 按給藥途徑
  • 按最終用戶
  • 按分銷渠道
  • 按地區

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第九章 監理架構與創新

  • 專利情況
  • 監管審批
  • 創新/新技術

第十章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT分析（5家進入市場的公司）
  • 專利分析（如果適用）

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Pfizer, Inc.
  • Novartis AG
  • Bausch Health Companies Inc.
  • REGENXBIO Inc.
  • F. Hoffmann-La Roche Ltd
  • 4D Molecular Therapeutics
  • Adverum Biotechnologies, Inc.
  • Santen Pharmaceuticals Co.
  • Bayer AG
  • Valent Pharmaceuticals International, Inc.

第十四章 戰略建議

第十五章 關於我們公司、免責聲明

Product Code: MX11050

Global age related macular degeneration market is projected to witness a CAGR of 9.6% during the forecast period 2024-2031, growing from USD 10.19 billion in 2023 to USD 21.22 billion in 2031F. The market witnessed significant growth in the recent years and is expected to further expand over the forecast period.

Age related macular degeneration (AMD) occur because of damage caused to macula due to aging. Macula is a part of retina, which is responsible for translating the light, that enters the eye, into images. It is responsible for central vision, allowing individuals to view objects directly in front of them. AMD is one of the leading causes of vision loss for older population. The different types of age related macular degeneration include dry AMD and wet AMD. Dry AMD occurs in three stages that include early, intermediate, and late. Wet AMD usually causes faster loss of vision, dry AMD can turn into wet AMD. It occurs due to abnormal blood vessel growth at the back of the eye, which causes damage to macula. According to an article published in Journal Cureus, in September 2022, it is estimated that 200 million people suffer from AMD. The number is projected to increase to roughly 300 million by 2040. The age related macular degeneration market growth can be attributed to the increased initiatives by various health agencies and NGOs across the globe to spread awareness about the adequate course of treatment and impact of the disease.

Increasing Investments by Market Players is Supporting Market Expansion

Owing to increasing prevalence of age-related macular degeneration in various regions across the globe, several market players and research institutions are investing towards the development of treatment options and early diagnostic solutions to combat the disease. For instance, Adverum Biotechnologies, Inc. is developing Ixoberogene soroparvovec (Ixo-vec) for the treatment of wet AMD. The clinical-stage gene therapy product candidate utilizes AAV.7m8, a propriety vector. Under the control of proprietary expression cassette, it carries an aflibercept coding sequence. Current care methods for wet AMD care require frequent anti-VEGF injections in the eyes, causing burden for both caregivers and patients. Adverum believes that Ixoberogene soroparvovec has the potential for providing cost effective, durable, and safe in-office treatment options that will address the requirements of retina specialists and healthcare systems across the globe as well as patients and their caregivers. The study conducted in patients demonstrated consistent and continuous therapeutic levels from Ixoberogene soroparvovec in study subjects with wet AMD.

Growing Prevalence in Aging Population to Boost the Market

The demand for AMD drugs is anticipated to increase over the forecast period, owing to rising aging population. As the risk for macular degeneration amongst the geriatric population is high, the market is expected to grow with the increasing number of older people. According to the World Health Organization, by 2030, 1 in 6 people living across the globe will age 60 and above. By 2050, the world's population aged 60 and above will reach 2.1 billion and by 2050 the number of individuals aging 80 years or older will reach 426 million.

The Centers for Disease Control and Prevention projects that 7.3 million individuals in America are at a heightened risk of loss of vision from age related macular degeneration and 1.8 million people suffer from the disease. These factors are bolstering the growth of the macular degeneration treatment market.

North America to Hold a Significant Share of the Market

The growth of geriatric population, strong presence of several market players, and increasing cases of age-related macular degeneration is supporting the expansion of the market in the region. It is estimated that approximately 20 million adults in the United States suffer from some sort of macular degeneration. As per Canadian Ophthalmological Society, age related macular disorder is one of the leading causes of blindness in Canada and as of February 2022, affects approximately 2 million Canadians.

The society is dedicated towards spreading awareness about the different treatments by highlighting the research conducted by Canadian ophthalmologists that are dedicated towards innovating new therapies that aim at enhancing the treatment for wet AMD. Promising age-related macular degeneration research is being conducted on several fronts. Various chemical trials are underway with novel therapies that aim at enhancing the treatment options for AMD. Such continuous investments and initiatives towards development of therapies for age related macular degeneration are further supporting the expansion of North America age related macular degeneration market.

Wet AMD Anticipated to Hold Significant Market Share

Wet age-related macular degeneration roughly accounts for 10% of cases, however, it results in 90% of cases of legal blindness. This disease is an advanced form of the AMD condition and can cause severe and rapid loss of vision. It occurs due to abnormal growth of blood vessels at the back of the eye, causing damage to macula. The current standard of care to aid the prevention of vision loss progression are anti-vascular endothelial growth factor (VEGF) therapies, however, these therapies require repeated intravitreal injections for the remainder of the patient's life. The highly demanding treatment schedule that requires injections every four to twelve weeks is expected to add to the overall demand in the market. Recently, an ophthalmologist at Mayo Clinic in Minnesota, the United States, performed the first subretinal gene therapy as a potential one-time treatment for wet age related macular degeneration as part of a clinical study of RGX-314.

New Developments in Eylea Injections

Eylea blocks the leakage of fluid caused by abnormal growth of blood vessels on the backside of the eye. In 2024, Molecular Therapeutics, linked their gene therapy to a reduction of wet AMD treatment burden by 90%, encouraging the organization to initiate planning for entry in phase 3 next year. An adeno-associated virus vector is used by 4D-150 for delivering transgenes encoding aflibercept. The aim is to eliminate the requirement for frequent injections of Eylea. In phase 2, 51 wet age-related macular degeneration patients at random, for eight weeks received injections of aflibercept or a shot of one of two doses of 4D-150. The patients on an average received 10 anti-VEGF injections in the previous year. By the twenty-four-week analysis, two-thirds of the patients that were on high dose, were injection free.

Future Market Scenario (2024 - 2031F)

Researchers from Anglia Ruskin University (ARU), have been working on developing a way to grow healthy retinal pigment epithelial (RPE) cells that can remain viable for up to 150 days. Retinal pigment epithelial cells are present outside the neural part of retina. The replacement of retinal pigment epithelial cells is one of the various promising therapeutic options available for effective treatment of age-related macular degeneration. Researchers are actively working on finding effective ways for transplanting these cells in eyes.

Recently Adverum Biotechnologies, Inc. released data from their optic extension study on patients suffering from wet age-related macular degeneration during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) annual meeting. The patients continued to experience long term benefits including reduction in anti-VEGF treatment burden and maintenance of vision.

Key Players Landscape and Outlook

Key participants in the age-related macular degeneration market include Bausch Health Companies Inc., REGENXBIO Inc., F. Hoffmann-La Roche Ltd, 4D Molecular Therapeutics, and Adverum Biotechnologies, Inc. The expansion of the aging population and increasing prevalence of age-related macular degeneration are providing lucrative growth opportunities to the market.

In 2023, Bausch+ Lomb Corporation, a subsidiary of Bausch Health Companies Inc., launched PreserVision AREDS 2 Formula eye vitamins plus coenzyme Q10 that combine the nutrient formula recommended by the NEI to aid in reducing the risk of moderate to advanced AMD progression. The global eye health company is dedicated towards helping their customers to live better lives.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Age-Related Macular Degeneration Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Disease
    • 4.2.1. Wet AMD
    • 4.2.2. Dry AMD
    • 4.2.3. Others
  • 4.3. Drug Type
    • 4.3.1. Aflibercept (Eylea)
    • 4.3.2. Ranibizumab (Lucentis)
    • 4.3.3. Bevacizumab (Avastin)
    • 4.3.4. Pegaptanib (Macugen)
    • 4.3.5. Verteporfin (Visudyne)
    • 4.3.6. Brolucizumab (Beovu)
    • 4.3.7. Supplements
    • 4.3.8. Others
  • 4.4. Route of Administration
    • 4.4.1. Intravenous
    • 4.4.2. Intravitreal
  • 4.5. End-user
    • 4.5.1. Immunology Hospitals
    • 4.5.2. Specialty Clinics
    • 4.5.3. Ambulatory Surgical Centers
    • 4.5.4. Home Healthcare
    • 4.5.5. Others
  • 4.6. Distribution Channel
    • 4.6.1. Hospital Pharmacies
    • 4.6.2. Retail Pharmacies
    • 4.6.3. Online Pharmacies
  • 4.7. Region
    • 4.7.1. North America
    • 4.7.2. South America
    • 4.7.3. Europe
    • 4.7.4. Asia-Pacific
    • 4.7.5. Middle East & Africa
  • 4.8. By Company Market Share (%), 2023

5. Global Age Related Macular Degeneration Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. Disease
      • 5.1.2.1. Wet AMD
      • 5.1.2.2. Dry AMD
      • 5.1.2.3. Others
    • 5.1.3. Drug Type
      • 5.1.3.1. Aflibercept (Eylea)
      • 5.1.3.2. Ranibizumab (Lucentis)
      • 5.1.3.3. Bevacizumab (Avastin)
      • 5.1.3.4. Pegaptanib (Macugen)
      • 5.1.3.5. Verteporfin (Visudyne)
      • 5.1.3.6. Brolucizumab (Beovu)
      • 5.1.3.7. Supplements
      • 5.1.3.8. Others
    • 5.1.4. Route of Administration
      • 5.1.4.1. Intravenous
      • 5.1.4.2. Intravitreal
    • 5.1.5. End-user
      • 5.1.5.1. Immunology Hospitals
      • 5.1.5.2. Specialty Clinics
      • 5.1.5.3. Ambulatory Surgical Centers
      • 5.1.5.4. Home Healthcare
      • 5.1.5.5. Others
    • 5.1.6. Distribution Channel
      • 5.1.6.1. Hospital Pharmacies
      • 5.1.6.2. Retail Pharmacies
      • 5.1.6.3. Online Pharmacies
    • 5.1.7. United States*
      • 5.1.7.1. Market Size & Forecast
      • 5.1.7.1.1. By Value
      • 5.1.7.1.2. By Volume
      • 5.1.7.2. Disease
      • 5.1.7.2.1. Wet AMD
      • 5.1.7.2.2. Dry AMD
      • 5.1.7.2.3. Others
      • 5.1.7.3. Drug Type
      • 5.1.7.3.1. Aflibercept (Eylea)
      • 5.1.7.3.2. Ranibizumab (Lucentis)
      • 5.1.7.3.3. Bevacizumab (Avastin)
      • 5.1.7.3.4. Pegaptanib (Macugen)
      • 5.1.7.3.5. Verteporfin (Visudyne)
      • 5.1.7.3.6. Brolucizumab (Beovu)
      • 5.1.7.3.7. Supplements
      • 5.1.7.3.8. Others
      • 5.1.7.4. Route of Administration
      • 5.1.7.4.1. Intravenous
      • 5.1.7.4.2. Intravitreal
      • 5.1.7.5. End-user
      • 5.1.7.5.1. Immunology Hospitals
      • 5.1.7.5.2. Specialty Clinics
      • 5.1.7.5.3. Ambulatory Surgical Centers
      • 5.1.7.5.4. Home Healthcare
      • 5.1.7.5.5. Others
      • 5.1.7.6. Distribution Channel
      • 5.1.7.6.1. Hospital Pharmacies
      • 5.1.7.6.2. Retail Pharmacies
      • 5.1.7.6.3. Online Pharmacies
    • 5.1.8. Canada
    • 5.1.9. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Disease
  • 6.2. By Drug Type
  • 6.3. By Route of Administration
  • 6.4. By End-user
  • 6.5. By Distribution Channel
  • 6.6. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Bausch Health Companies Inc.
  • 13.4. REGENXBIO Inc.
  • 13.5. F. Hoffmann-La Roche Ltd
  • 13.6. 4D Molecular Therapeutics
  • 13.7. Adverum Biotechnologies, Inc.
  • 13.8. Santen Pharmaceuticals Co.
  • 13.9. Bayer AG
  • 13.10. Valent Pharmaceuticals International, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 4. Global Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 5. Global Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6. Global Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 8. Global Age Related Macular Degeneration Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 12. North America Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 13. North America Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 14. North America Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 15. North America Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 16. North America Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 20. United States Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 21. United States Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. United States Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 23. United States Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 24. Canada Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 27. Canada Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 28. Canada Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 29. Canada Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 30. Canada Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 31. Mexico Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 34. Mexico Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 35. Mexico Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 36. Mexico Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 37. Mexico Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 38. Europe Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 41. Europe Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 42. Europe Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. Europe Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 44. Europe Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 45. Europe Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 49. Germany Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 50. Germany Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51. Germany Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 52. Germany Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 53. France Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 56. France Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 57. France Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. France Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 59. France Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 60. Italy Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 63. Italy Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 64. Italy Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 65. Italy Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 66. Italy Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 67. United Kingdom Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 70. United Kingdom Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 71. United Kingdom Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 72. United Kingdom Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 73. United Kingdom Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Russia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 77. Russia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 78. Russia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 79. Russia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 80. Russia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 81. Netherlands Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 84. Netherlands Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 85. Netherlands Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Netherlands Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 87. Netherlands Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Spain Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 91. Spain Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 92. Spain Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93. Spain Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 94. Spain Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Turkey Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 98. Turkey Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 99. Turkey Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100. Turkey Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 101. Turkey Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 102. Poland Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 105. Poland Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 106. Poland Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 107. Poland Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 108. Poland Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 109. South America Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 112. South America Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 113. South America Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 114. South America Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 115. South America Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. South America Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 120. Brazil Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 121. Brazil Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 122. Brazil Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 123. Brazil Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 124. Argentina Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 127. Argentina Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 128. Argentina Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 129. Argentina Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 130. Argentina Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Asia-Pacific Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 134. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 135. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Asia-Pacific Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 137. Asia- Pacific Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Asia-Pacific Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 139. India Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 142. India Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 143. India Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 144. India Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 145. India Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. China Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 149. China Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 150. China Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. China Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 152. China Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 153. Japan Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 156. Japan Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 157. Japan Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 158. Japan Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 159. Japan Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 160. Australia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 163. Australia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 164. Australia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 165. Australia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 166. Australia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 167. Vietnam Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 170. Vietnam Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 171. Vietnam Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Vietnam Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 173. Vietnam Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. South Korea Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 177. South Korea Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 178. South Korea Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. South Korea Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 180. South Korea Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. Indonesia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 184. Indonesia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 185. Indonesia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186. Indonesia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 187. Indonesia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 188. Philippines Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 191. Philippines Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 192. Philippines Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 193. Philippines Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 194. Philippines Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 195. Middle East & Africa Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 198. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 199. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 200. Middle East & Africa Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 201. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 202. Middle East & Africa Age Related Macular Degeneration Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 206. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 207. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 208. Saudi Arabia Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 209. Saudi Arabia Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 210. UAE Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 213. UAE Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 214. UAE Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 215. UAE Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 216. UAE Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 217. South Africa Age Related Macular Degeneration Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Age Related Macular Degeneration Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Age Related Macular Degeneration Market Share (%), By Disease, 2017-2031F
  • Figure 220. South Africa Age Related Macular Degeneration Market Share (%), By Drug Type, 2017-2031F
  • Figure 221. South Africa Age Related Macular Degeneration Market Share (%), By Route of Administration, 2017-2031F
  • Figure 222. South Africa Age Related Macular Degeneration Market Share (%), By End-user, 2017-2031F
  • Figure 223. South Africa Age Related Macular Degeneration Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 224. By Disease Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023